5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure


 

NCCN Guidelines Update for ER+ Breast Cancer: CDK4/6 and PIK3CA Inhibitors for Advanced BC & Tamoxifen and Aromatase Inhibitors for Early BC

9,370 views
September 13, 2019
Comments 1
Login to view comments. Click here to Login